American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
Black Hawk Acquisition Corp
$11.89
+0.25%
NASDAQ: BKHA · 15-min delayed
$49.3MMarket cap
$1.3MNet income
BKHANASDAQ
2024IPO
About Black Hawk Acquisition Corp
Black Hawk Acquisition Corp is a Blank check company.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Net income
- $1.3M
- Total assets
- $23.9M
- Market cap
- $49.3M
- Operating margin
- -40.5%
- Net margin
- 58.9%
Source: SEC EDGAR · updated Jun 8, 2026
Multi-year
Revenue & profit trend
FY2024
FY2025
Revenue Net income
FY 2025
Financial statements
Income statement
- Revenue
- $2.3M
- Operating expenses
- $3.2M
- Operating income
- -$915.5K
- Net income
- $1.3M
Balance sheet
- Total assets
- $23.9M
- Current assets
- $50.8K
- Total liabilities
- $3.9M
- Current liabilities
- $1.5M
- Shareholders’ equity
- -$3.8M
Cash flow
- Operating cash flow
- -$650.3K
- Investing cash flow
- $50.3M
- Financing cash flow
- -$49.8M
- Net cash flow
- -$225.3K
Statements via Polygon.io (SEC filings)
NASDAQ: BKHA
$11.89
+0.25%
15-minute delayed · data by Polygon.io
Past year
$10.57
$11.95
52-week range
- Market cap
- $49.3M
- Shares outstanding
- 4.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 13, 2024
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Profitable — net income of $1.3M.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Black Hawk Acquisition Corp.
Write a review
Newsroom
News about Black Hawk Acquisition Corp
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles
News & sentiment via Polygon.io
Explore
Browse all →
